PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:42:10 2024-06-28 pm EDT | ||
| 0.53 EUR | +10.42% |
|
| Current month | -66.46% | ||
| 1 month | -67.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.53 | +10.42% |
| 24-06-27 | 0.48 | -9.43% |
| 24-06-26 | 0.53 | +96.30% |
| 24-06-25 | 0.27 | -60.29% |
| 24-06-24 | 0.68 | -8.11% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 01:42 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0KK5 |
| ISIN | DE000VD0KK58 |
| Date issued | 2024-02-19 |
| Strike | 1,038 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.08 € |
|---|---|
| Lowest since issue | 0.22 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
